INNOVIVE Pharmaceuticals Licenses WT1 Peptide Cancer Immunotherapeutic
INNOVIVE Pharmaceuticals Licenses WT1 Peptide Cancer Immunotherapeutic
Genetic Engineering News – Vaccine is First WT1 Heteroclitic Peptide Immunotherapeutic to Specifically Target CD4 and CD8 Activation INNOVIVE Pharmaceuticals Inc., a biopharmaceutical company headquartered in Manhattan, announced today that it has licensed worldwide
